Article Text

Download PDFPDF
EP569 Potential role of PAI-1 in endometrial cancer progression and its regulation by epigenetic mechanisms
  1. J Marí-Alexandre1,
  2. C Agababyan2,
  3. P Pascual-Utiel1,
  4. M Cubertorer-Navarro1,
  5. J García-Oms2,
  6. A Estellés3 and
  7. J Gilabert-Estellés1,2,4
  1. 1Laboratorio Investigación Biomarcadores en Reproducción, Ginecología y Obstetricia, Fundación de Investigación Hospital General Universitario de Valencia
  2. 2Servicio de Obstetricia y Ginecología, Hospital General Universitario de Valencia
  3. 3Hospital Universitario y Politécnico La Fe
  4. 4Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain


Introduction/Background Endometrial cancer (EC) is the most prevalent gyneacological cancer. It presents two subtypes, (Type-1 and Type-2), being the lately associated to worse prognosis and increased epithelial-to-mesenchymal transition (EMT). A growing evidence supports that uPA and PAI-1 play a role in solid tumour progression, though the exact role of PAI-1 and its epigenetic regulation in EC has not been completely established yet.

Methodology 67 patients with EC and 36 control women were included. 5 miRNAs targeting PAI-1 mRNA (namely miR-99a-5p, miR-143-3p, miR-145-5p, miR-196b-5p y miR-301a-3p) were selected from miRNA expression profiles (Affymetrix, GeneChipmiRNA 2.0) and validated by RT-qPCR. mRNA levels of E-cadherin, Vimentin, Fibronectin, Snail1 and Twist were assessed by RT-qPCR; PAI-1 tissue and plasma levels by ELISA (DuoSet).

Results At the tissue level, PAI-1 is over-expressed in EC in comparison to control endometria (CE) (88.67±12.65 vs. 65.89±9.39 pg/mg), and is significantly increased in Type-2 vs. Type-1 EC (124.43±18.31 vs. 65.90±13.57 pg/mg; p=0.02). At the plasma level, PAI-1 increases in EC vs. control plasma (3.06±0.34 vs. 0.99±0.19 ng/mL, p<0.001), but is reduced in Type-2 vs. Type-1 EC (1.75±0.38 vs. 3.49±0.46 ng/mL; p=0.01). The levels of miR-196b-5p were significantly reduced in EC vs. CE (0.42±0.12 vs.1.00±0.27; p<0.05), inversely correlating with PAI-1 levels, especially in Type-2 EC. Nevertheless, miR-301a-3p is significantly increased in EC vs. CE (1.90±0.30 vs. 1.00±0.16; p<0.05), which could act via targeting PTEN. Finally, we observed decreased levels of E-Cadherin (1.00±0.12 vs. 0.57±0.20; p<0.01) and increased levels of Snail1 and Twist1 in Type-2 vs. Type-1 EC (1.00±0.17 vs. 3.49±0.90; p<0.01; 1.00±0.16 vs. 3.56±1.18; p<0.01; respectively).

Conclusion PAI-1 plasma and tissue levels are over-expressed in EC vs. CE, but only in tissues it is over-expressed in the worst-prognose subtype, which is associated with increased EMT markers. This local action of PAI-1 might be mediated by down-regulation of miR-196b-5p.

Disclosure All authors have declared no conflicts of interest. This work has been supported by grants from ISCIII (PI17/01945). J. M-A. is supported by a FETH 2016-2018 award and a post-doctoral grant (APOSTD/2019/087).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.